Lisata Therapeutics Inc (LSTA) — Smart Money Tracker (13F, Q2 2026)

Lisata Therapeutics (ticker: LSTA) announced on August 3, 2026 that its board approved an immediate workforce reduction of approximately 72% to cut operating costs and position the company to pursue strategic options. The company estimates it will incur about $1.2 million in severance and related termination costs, expected through the quarter ending September 30, 2026. Affected employees will receive separation benefits, including severance pay and temporary healthcare coverage for some.

Lisata Therapeutics (ticker LSTA) terminated its merger agreement with Kuva Labs and its acquisition subsidiary on July 24, 2026. The deal, which valued Lisata at $4.00 per share in cash plus up to $3.00 per share in contingent value rights (CVRs), fell apart because Kuva failed to secure the financing needed to complete the tender offer by the July 20 deadline.

Lisata Therapeutics extended the deadline to complete its merger with Kuva Labs by four days, from July 17 to July 21, 2026. The amendment was signed on July 16 and relates to the merger agreement originally dated March 6, 2026.